Prospective observational study protocol to investigate long-term adverse effects of methylphenidate in children and adolescents with ADHD: the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study

S K Inglis, S Carucci, P Garas, A Häge, T Banaschewski, J K Buitelaar, R W Dittmann, B Falissard, C Hollis, H Kovshoff, E Liddle, S McCarthy, P Nagy, A Neubert, E Rosenthal, E Sonuga-Barke, I Wong, A Zuddas, D C Coghill, ADDUCE Consortium, S K Inglis, S Carucci, P Garas, A Häge, T Banaschewski, J K Buitelaar, R W Dittmann, B Falissard, C Hollis, H Kovshoff, E Liddle, S McCarthy, P Nagy, A Neubert, E Rosenthal, E Sonuga-Barke, I Wong, A Zuddas, D C Coghill, ADDUCE Consortium

Abstract

Introduction: Methylphenidate is the most frequently used medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in Europe. Following concerns about its safety, the European Commission called for research into the long-term effects of methylphenidate on children and adolescents with ADHD. The Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) research programme was designed to address this call. At the heart of this programme is a 2-year longitudinal naturalistic pharmacovigilance study being conducted in 27 European sites.

Methods and analysis: 3 cohorts of children and adolescents (aged 6-17) living in the UK, Germany, Italy and Hungary are being recruited:Group 1 (Medicated ADHD): 800 ADHD medication-naive children and adolescents with a clinical diagnosis of ADHD about to start methylphenidate treatment for the first time.Group 2 (Unmedicated ADHD): 400 children and adolescents with a clinical diagnosis of ADHD who have never been treated with ADHD medication and have no intention of beginning medication.Group 3 (Non-ADHD): 400 children and adolescents without ADHD who are siblings of individuals in either group 1 or 2.All participants will be assessed 5 times during their 2-year follow-up period for growth and development, psychiatric, neurological and cardiovascular health. The primary outcome measure will be the height velocity SD score.

Ethics and dissemination: Ethical approval for the study has been granted by the East of Scotland Research Ethics Service. Following this approval, patient information leaflets and consent forms were translated as necessary and submissions made by lead sites in each of the other 3 countries to their own ethics committees. Following ethical approval in each country, local ethical permissions at each site were sought and obtained as needed. The study's website (http://www.adhd-adduce.org/page/view/2/Home) provides information for researchers, participants and the general public.

Trial registration number: NCT01470261.

Keywords: Attention Deficit Hyperactivity Disorder; Methylphenidate.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Study design flow chart.

References

    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association, 2013.
    1. Polanczyk G, de Lima MS, Horta BL et al. . The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942–8. 10.1176/ajp.2007.164.6.942
    1. Taylor E, Dopfner M, Sergeant J et al. . European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):I7–30. 10.1007/s00787-004-1002-x
    1. National Institute for Health and Clinical Excellence (NICE). Diagnosis and management of ADHD in children, young people and adults, 2013. National Clinical Practice Guideline Number 72.
    1. Volkow ND, Wang GJ, Fowler JS et al. . Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002;43:181–7. 10.1002/syn.10038
    1. Greenhill LL. Clinical effects of stimulant medications. In: Solanto MV, Arnsten AFT, Castellanos FX, eds. Stimulant drugs and ADHD. New York: Oxford University Press, 2001:31–71.
    1. Care Commission. The safer management of controlled drugs. 2012.
    1. Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int 2010;107:615–21. 10.3238/arztebl.2010.0615
    1. Janols LO, Liliemark J, Klintberg K et al. . Central stimulants in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. A naturalistic study of the prescription in Sweden, 1977-2007. Nord J Psychiatry 2009;63:508–16.
    1. Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription among school-aged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. J Atten Disord 2010;14:267–72. 10.1177/1087054709356386
    1. Criado-Alvarez JJ, Romo-Barrientos C. [Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention deficit hyperactivity disorder]. Rev Neurol 2003;37:806–10.
    1. Visser SN, Danielson ML, Bitsko RH et al. . Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry 2014;53:34–46.e2. 10.1016/j.jaac.2013.09.001
    1. Man KK, Ip P, Hsia Y et al. . ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong. J Atten Disord 2014. doi: 108705471453604710.1177/1087054714536047
    1. European Union. Community referral 2007.
    1. European Union. Understanding community referrals 2013.
    1. European Union. Referrals document 2009.
    1. European Union. 4th Call of the European Commission's Framework Programme (FP7) 2009.
    1. ADDUCE consortium. Attention Deficit Hyperactvity Drugs Use Chronic Effects.
    1. Faraone SV, Biederman J, Morley CP et al. . Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:994–1009. 10.1097/CHI.ObO13e31817eOea7
    1. Poulton A. Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 2005;90:801–6. 10.1136/adc.2004.056952
    1. Poulton AS, Melzer E, Tait PR et al. . Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. Med J Aust 2013;198:29–32. 10.5694/mja12.10931
    1. Swanson J, Arnold LE, Kraemer H et al. . Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. J Atten Disord 2008;12:4–14. 10.1177/1087054708319345
    1. Swanson J, Arnold LE, Kraemer H et al. . Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of children with ADHD (MTA): part II: supporting details. J Atten Disord 2008;12:15–43. 10.1177/1087054708319525
    1. Iversen L. Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 2006;147:S82–8. 10.1038/sj.bjp.0706428
    1. Vetter VL, Elia J, Erickson C et al. . Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407–23. 10.1161/CIRCULATIONAHA.107.189473
    1. Howes OD, Kambeitz J, Kim E et al. . The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012;69:776–86. 10.1001/archgenpsychiatry.2012.169
    1. Bussing R, Fernandez M, Harwood M et al. . Parent and teacher SNAP-IV ratings of attention deficit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 2008;15:317–28. 10.1177/1073191107313888
    1. Goodman R. Psychometric properties of the strengths and difficulties questionnaire. J Am Acad Child Adolesc Psychiatry 2001;40:1337–45. 10.1097/00004583-200111000-00015
    1. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I. Arch Dis Child 1966;41:454–71. 10.1136/adc.41.219.454
    1. Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966;41:613–35. 10.1136/adc.41.220.613
    1. Preuss U, Ralston SJ, Baldursson G et al. , ADORE Study Group. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):I4–14. 10.1007/s00787-006-1002-0
    1. Scottish Children's Research Network. Standard Operating Procedure.
    1. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13–23. 10.1136/adc.45.239.13
    1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303. 10.1136/adc.44.235.291
    1. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD, USA: Department of Health, Education, and Welfare, 1976.
    1. Shaffer D, Gould MS, Brasic J et al. . A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228–31. 10.1001/archpsyc.1983.01790100074010
    1. Wilson BN, Crawford SG, Green D et al. . Psychometric properties of the revised Developmental Coordination Disorder Questionnaire. Phys Occup Ther Pediatr 2009;29:182–202. 10.1080/01942630902784761
    1. Berument SK, Rutter M, Lord C et al. . Autism screening questionnaire: diagnostic validity. Br J Psychiatry 1999;175:444–51. 10.1192/bjp.175.5.444
    1. Angold A, Costello EJ, Messer SC et al. . The development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. Int J Methods Psychiatr Res 1995;5:237–49.
    1. Zammit S, Horwood J, Thompson A et al. . Investigating if psychosis-like symptoms (PLIKS) are associated with family history of schizophrenia or paternal age in the ALSPAC birth cohort. Schizophr Res 2008;104:279–86. 10.1016/j.schres.2008.04.036
    1. Goodman R, Ford T, Richards H et al. . The Development and Well-Being Assessment: description and initial validation of an integrated assessment of child and adolescent psychopathology. J Child Psychol Psychiatry 2000;41:645–55. 10.1111/j.1469-7610.2000.tb02345.x
    1. Leckman JF, Riddle MA, Hardin MT et al. . The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566–73. 10.1097/00004583-198907000-00015
    1. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003;112:497–507. 10.1037/0021-843X.112.3.497
    1. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988;39:1172–7.
    1. Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep 2000;23:1043–51.
    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555–76.
    1. Tayside Clinical Trials Unit. Tayside Clinical Trials Unit 2014.
    1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Good Clinical Practice 1996.
    1. Pliszka SR, Matthews TL, Braslow KJ et al. . Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:520–6. 10.1097/01.chi.0000205702.48324.fd
    1. Charach A, Figueroa M, Chen S et al. . Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 2006;45:415–21. 10.1097/01.chi.0000199026.91699.20
    1. Zhang H, Du M, Zhuang S. Impact of long-term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics 2010;41:55–9. 10.1055/s-0030-1261893
    1. Klein RG, Landa B, Mattes JA et al. . Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 1988;45:1127–30. 10.1001/archpsyc.1988.01800360075011
    1. Hechtman L, Weiss G, Perlman T. Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 1984;23:261–9. 10.1016/S0002-7138(09)60501-X
    1. Tanner JM, Whitehouse RH, Marshall WA et al. . Prediction of adult height from height, bone age, and occurrence of menarche, at ages 4 to 16 with allowance for midparent height. Arch Dis Child 1975;50:14–26. 10.1136/adc.50.1.14
    1. Pyle SI, Waterhouse AM, Greulich WW. Attributes of the radiographic standard of reference for the National Health Examination Survey. Am J Phys Anthropol 1971;35:331–7. 10.1002/ajpa.1330350306
    1. Health Informatics Centre. Health Informatics Centre Services. 10.1002/prot.24083
    1. OpenClinica. OpenClinica Open Source for Clinical Research.
    1. World Medical Association. Declaration of Helsinki—ethical principles for medical research involving human subjects.
    1. The Scottish Government. Research Governance.
    1. Barkley RA, Macias M. Attention deficit hyperactivity disorder. In: David R, ed. Child and adolescent neurology. 3rd edn New York: Blackwell, 2005.
    1. Graham J, Banaschewski T, Buitelaar J et al. . European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17–37. 10.1007/s00787-010-0140-6
    1. Kendall T, Taylor E, Perez A et al. . Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ 2008;337:a1239 10.1136/bmj.a1239
    1. Posner K, Brown GK, Stanley B et al. . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266–77. 10.1176/appi.ajp.2011.10111704

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere